Abbott recently announced that its molecular test, the Abbott RealTime Zika Test, has been authorized by the U.S. Food and Drug Administration (FDA). Read More »

Mylan N.V. recently released a statement in response to a Financial Times article entitled “HIV/Aids drug for developing world face threat of disruption.” Read More »

Personal Genome Diagnostics Inc. has received a National Cancer Institute contract to develop a novel diagnostic for helping identify patients who are most likely to benefit from cancer drugs called checkpoint inhibitors. Read More »

DrFirst, an electronic prescribing company, has acquired VisibilityRx, a provider of clinical trial recruitment services to life sciences, clinical research organizations and pharmacies. Read More »

TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha. Read More »

Puma Biologics reports the U.S. Food and Drug Administration has posted the documents that were used for briefing at the Oncologic Drugs Advisory Committee (ODAC) May 24. Read More »

AM-Pharma B.V. has finished recruiting for its Phase II trial of treatment for individuals with Acute Kidney Injury. Read More »

Janssen Research & Development LLC has identified new partnerships through the company’s Janssen Human Microbiome Institute, a program that develops microbial products through innovation and discovery. Read More »

Allergan PLC, a global biopharmaceutical company, recently concluded its $2.9 billion acquisition of LifeCell Corp., a business that develops regenerative medicine. Read More »

Otsuka Pharmaceutical has entered into a licensing agreement that gives it exclusive rights to develop and commercialize Teva Pharmaceutical Industries' migraine prevention drug fremanezumab in Japan. Read More »